Peter Hofland

The Onco'Zine Brief

Science EN ↓ 107 episodes

The Onco'Zine Brief is an interview and discussion program presented by Peter Hofland and covers a broad range of topics and timely news updates with information from all oncology disciplines and sub-specialties from around the world. The Onco'Zine Brief is a sponsor-supported, program for healthcare professionals involved in the management and care of cancer patients as well as cancer patients and their family and friends. If you like to join us as a sponsor or advertisers, download our media kit ( https://adc.expert/oncozine_media_kit) . If you are living in the US, sign up for our newslette...

Author

Peter Hofland

Category

Science

Podcast website

www.spreaker.com

Latest episode

Nov 30, 2023

Where to listen?

Podcasts in the app Replaio Radio Coming soon

Podcasts are coming to the app soon. Install now and be the first to see a whole new take on podcasts

Get it on Google Play Install for free Android 5M+ downloads · 4.8 rating iOS soon

Episodes

Dr. Google Calling MedAnswers: How to find Personalized Answers to Pressing Medical Questions 16.12.2017

In this episode of The Onco'Zine Brief Peter Hofland and Sonia Portillo talk with Alice Crisci. Alice is a cancer survivor. As part of her journey to survival Crisci founded Fertile Action, a cancer charity established to ensure fertile people touched by cancer can become mothers. As a cancer survivor and a single mom who faced issues of infertility, Alice dealt with the challenges of figuring out...

An Urgent Need to Impact Lung Cancer Care in a Big Way 16.12.2017

Each year, 1.4 million people are diagnosed with lung cancer worldwide. The 5-year survival rate for these patients is only 15.9%. In this episode of the Peter Hofland and Sonia Portillo, the team behind The Onco'Zine Brief, interview Bonnie Adario, Cancer Survivor. Addario was was first diagnosed with stage 3b lung cancer in 2004, a cancer with a survival rate of only 5%. As part of her treatment...

Superblood: The Development of Novel Red-Cell Therapeutics 16.12.2017

In this episode of The Onco'Zine Brief, Peter Hofland and Sonia Portillo, talk with David R. Epstein B.Sc, MBA, the Executive Chairman of Rubius Therapeutics. Epstein explains how his company is pioneering novel Red-Cell Therapeutics or RCTs – nicknamed ‘superblood’ – as a new class of medicines to address a wide array of diseases. He explains how these novel drugs have leading applications in can...

The Impact of New Therapies in the Treatment of Lung Cancer 16.12.2017

Lung cancer remains one of the most frequently diagnosed cancers. It is also one of the deadliest cancers – with each year more than 1.6 million tumor-related deaths worldwide. The correlation between smoking and mortality from lung cancer has been clearly confirmed and a decrease of mortality after cessation of tobacco use has been seen in the United States. Since the 1990s first in men and later...

Novel Drugs Leading the Way to Progress in the Treatment of Multiple Myeloma 16.12.2017

In this episode of The Onco'Zine Brief, Peter Hofland and Sonia Portillo talk with Robert Z. Orlowski, MD, PhD, chairman, Ad Interim, Director of Myeloma and Professor of Medicine in the Departments of Lymphoma, Myeloma and Experimental Therapeutics in the Division of Cancer Medicine at MD Anderson in Houston, Texas. They ask Orlowski about his thoughts and unique perspective on research and the r...

A new Paradigm in the Development and Manufacturing of Antibody-drug Conjugates 16.12.2017

In this episode of The Onco'Zine Brief, recorded during CPhI World Wide, held October 24 - 27, 2017 in Frankfurt, Germany, Peter Hofland and Sonia Portillo, interview Charlie Johnson, the CEO of ADC Bio. ADC Bio, a biotechnology company developing new process technology to speed, simplify and significantly lower the production costs of the latest generation of novel anti-cancer blockbuster drugs k...

Alcohol, a Modifiable Risk Factor for Cancer 16.12.2017

Even modest use of alcohol may increase cancer risk. The greatest risks are observed with heavy, long-term use of alcohol. Now, for the first time, the American Society of Clinical Oncology (ASCO) has formally recognized that alcohol drinking is a risk factor for multiple malignancies. This risk is, however, potentially modifiable. Become a supporter of this podcast: https://www.spreaker.com/podca...

Listen to the The Onco'Zine Brief podcast in Replaio

Radio and podcasts in one app - free, with no sign-up. Install today and do not miss the launch

Get it on Google Play

Replaio is not a podcast publisher; show names, artwork and audio belong to their authors and are distributed through public RSS feeds.